Reduce ADC Conjugation Risk with Consistent Antibody Quality

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads for targeted oncology. While an ADC consists of an antibody, linker and payload, the antibody provides the targeting capability needed for selective delivery to tumor cells. Its quality, consistency and stability are therefore critical to successful conjugation, downstream processing and final ADC performance.

This webinar will explore key development considerations for antibodies intended for ADC therapies, including antigen specificity, binding strength, structural stability and readiness for chemical conjugation. The discussion will examine why antibody molecules must maintain consistent quality attributes throughout development and manufacturing, especially as they move toward conjugation with potent payloads.

Participants will also learn how cell line development and upstream production processes affect antibody output and how downstream purification workflows help isolate the antibody and remove impurities before the molecule advances to payload attachment.

As ADC programs progress from early development toward clinical and commercial manufacturing, scale-up introduces additional requirements for reproducibility, process characterization and control of product quality attributes. The session will address how maintaining stable antibody quality during manufacturing scale-up can support efficient conjugation, reduce variability and contribute to more predictable final ADC performance.

A featured success story will illustrate how variability in antibody glycosylation patterns affected conjugation efficiency and how upstream process optimization improved consistency in antibody quality attributes and overall manufacturing performance.

The webinar will also highlight how experienced CDMO support can help development teams establish reliable antibody production processes, address quality variability and progress toward downstream conjugation and commercial readiness. Attendees will gain a clearer understanding of how antibody manufacturing and scale-up decisions affect ADC development and support targeted oncology programs.

Register for this webinar to learn how ADC manufacturing strategies can improve antibody consistency, support efficient conjugation and reduce scale-up risk.

Speaker

Dave Briggs, PhD, MSAT Principal Scientist, Late Stage/Commercial, Avid Bioservices

Dave Briggs, PhD, brings extensive experience in biopharmaceutical manufacturing, spanning purification R&D, downstream process development, manufacturing operations, process validation and continued process verification. Throughout his career, he has supported the development, transfer, validation and commercialization of biologic processes, with a focus on translating scientific understanding into robust, scalable and compliant manufacturing solutions.

As a Principal Scientist in Manufacturing Science and Technology (MSAT), Late Stage/Commercial, at Avid Bioservices, Dave leads cross-functional initiatives supporting process performance qualification, lifecycle management, process monitoring and continuous improvement of commercial manufacturing processes. He is recognized for applying data-driven approaches to enhance process robustness, ensure regulatory compliance and drive operational excellence across the product lifecycle.

Dave holds a PhD in Molecular and Cellular Biology from the University of Arizona and a BSc in Microbiology from Brigham Young University. His expertise spans downstream processing, chromatography, technology transfer, process validation, manufacturing science and continued process verification, with a passion for transforming complex technical challenges into practical solutions that enable reliable and efficient biologics manufacturing.

Message Presenter